Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Xanthine oxidase-IN-4 (compound 19a) is an orally active and potent inhibitor of xanthine oxidase(XO) with an IC 50 of 0.039 μM that can be used in the research of hyperuricemia and gout. Xanthine oxidase-IN-4 shows hypouricemic potency in potassium oxonate induced hyperuricemia rats. [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,520.00 | |
50 mg | 6-8 weeks | $ 1,980.00 | |
100 mg | 6-8 weeks | $ 2,500.00 |
Description | Xanthine oxidase-IN-4 (compound 19a) is an orally active and potent inhibitor of xanthine oxidase(XO) with an IC 50 of 0.039 μM that can be used in the research of hyperuricemia and gout. Xanthine oxidase-IN-4 shows hypouricemic potency in potassium oxonate induced hyperuricemia rats. [1]. |
In vitro | Xanthine oxidase-IN-4 (compound 19a), at concentrations ranging from 1 nM to 10 μM over 15 minutes, demonstrates significant inhibitory activity against xanthine oxidase, showcasing an IC50 value of 0.039 μM and a Ki value of 0.0037 μM [1]. |
In vivo | Xanthine oxidase-IN-4 (compound 19a), administered intragastrically at a dose of 10 mg/kg to Sprague-Dawley rats (six weeks old, male, 180-200g, divided into six groups), significantly reduced the serum uric acid concentration. This effect was quantified by a 44.3% reduction in the area under the curve (AUC) for serum uric acid levels measured between 1 and 5 hours post-dose. |
Molecular Weight | 295.3 |
Formula | C15H13N5O2 |
CAS No. | 2642137-96-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Xanthine oxidase-IN-4 2642137-96-8 inhibitor inhibit